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Drug-induced liver injury (DILI) is a major concern for
public health. Several forms of DILI are associated with
the expression of specific MHC genes suggesting that
the adaptive immune system is involved in the disease
pathogenesis. We have identified drug-responsive
T-cells in patients with flucloxacillin induced DILI and
shown that the drug antigen is presented to T-cells in
the context of the HLA risk allele (HLA-B*5701). The
combination of amoxicillin and clavulanic acid (co-
amoxiclav) is one of the most frequently prescribed
drugs. Occasionally, human exposure is associated with
DILI. Individual susceptibility can be influenced by HLA
genotypes (e.g. DRB1*1501 risk; DRB1*07:01 risk) and
we have recently characterized drug-specific T-cells in
patients with co-amoxiclav-induced DILI. The objective
of this study was to use amoxicillin-specific CD4+ T-cell
clones from 2 DILI patients to investigate the mechan-
isms of drug antigen presentation and to identify
susceptible HLA class II genotypes based on analysis of
drug specific T-cell responses.
Method
Antigen presenting cells (APC) expressing different HLA
alleles generated from our HLA-typed PBMC cell bank
were used to investigate the latter. EBV-transformed B-cell
lines from 15 donors expressing HLA alleles of interest
were generated and used as APC. To characterize
mechanism(s) of T-cell activation, APC were (1) omitted
from the assay, (2) pulsed with amoxicillin for 1-16h and
(3) treated with MHC blocking antibodies.
Results
The clones showed a strong proliferative response and
IFN secretion following exposure to amoxicillin and
autologous APC. Activation of the clones was also
observed with APC pulsed with amoxicillin for 16h. The
response was strongly inhibited with an anti-HLA class
II antibody. More detailed analysis using HLA-DR, -DP
and -DQ antibodies revealed that the response was
HLA-DR restricted. Allogeneic APC were then used to
define HLA-DR alleles involved in the drug-specific
response. Clones were activated with amoxicillin and
allogeneic APC expressing a range of DRB1 alleles
including 03:01, 04:01, 13:01 and 15:01. In contrast,
amoxicillin did not activate the clones with APC expres-
sing HLA-DRB1*01:01 and 07:01.
Conclusion
These findings characterizing HLA-restricted amoxicillin-
specific T-cell responses agree with recent genome-wide
association studies which identify specific HLA-DRB1
alleles as risk factors that influence susceptibility to
co-amoxiclav-induced liver injury.
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